drugset / Trial / NCT02757625

Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit

NCT02757625

Phase 3 Completed 63 enrolled Pfizer Maruishi Pharmaceutical · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects \[≥ 45 weeks CGA (corrected gestational age) to \<17 years old\] requiring sedation under intensive care unit

Timeline

Start
2016-07-20
Primary completion
2017-05-24
Completion
2017-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.2 ug/kg Intravenous

Indications

No indication recorded.